文献速递眼底病与葡萄膜炎

脉络膜上腔注射CLS-TA治疗非感染性葡萄膜炎继发黄斑水肿的3期随机试验

Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial.
PubMed 文献 · Ophthalmology · 2020-01-10

第24周时,CLS-TA组47%的患者BCVA提高≥15个ETDRS字母,对照组为16%(P<0.001);黄斑中心亚区厚度平均分别下降153 μm和18 μm(P<0.001)。未报告与治疗相关的严重不良事件。

要点

  • 脉络膜上腔注射CLS-TA在第24周使47%患者BCVA提高≥15个ETDRS字母,优于假治疗(16%)。
  • CLS-TA组黄斑中心亚区厚度平均下降153 μm,对照组下降18 μm。
  • 眼压升高不良事件在CLS-TA组和对照组分别为11.5%和15.6%。

核心结论

  • 脉络膜上腔注射CLS-TA较假治疗可显著改善非感染性葡萄膜炎继发黄斑水肿患者的视力,达到主要终点。

主要发现

  • 第24周BCVA提高≥15个ETDRS字母的患者比例CLS-TA组为47%、对照组为16%(P<0.001)。
  • 第24周黄斑中心亚区厚度较基线平均下降CLS-TA组153 μm、对照组18 μm(P<0.001)。
  • 未报告与治疗相关的严重不良事件。
  • 眼压升高不良事件发生率CLS-TA组11.5%、对照组15.6%,白内障不良事件发生率分别为7.3%和6.3%。

关键数值与推荐

  • 入组要求研究眼BCVA≥5个ETDRS字母(Snellen等效20/800)且≤70个ETDRS字母(Snellen等效20/40)。
  • 主要终点为第24周BCVA较基线提高≥15个ETDRS字母。
  • 次要终点为第24周黄斑中心亚区厚度较基线下降。

临床怎么用

  • 对于非感染性葡萄膜炎继发黄斑水肿且视力在20/800至20/40之间的患者,可考虑脉络膜上腔注射CLS-TA以改善视力并降低黄斑中心亚区厚度。
  • 治疗过程中需关注眼压升高和白内障等皮质类固醇相关不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Injection of pharmacotherapy into the suprachoroidal space, between the sclera and choroid, is an alternative delivery technique developed with the rationale of providing higher drug concentrations to posterior ocular structures compared with other intraocular and periocular injection procedures. This study was conducted to evaluate the safety and efficacy of suprachoroidally injected triamcinolone acetonide formulation (CLS-TA), a suspension of triamcinolone acetonide, in improving vision among patients with noninfectious uveitis complicated by macular edema (ME). DESIGN: Phase 3 masked, randomized trial. PARTICIPANTS: One hundred sixty patients with ME secondary to noninfectious uveitis. Patients were required to have a best-corrected visual acuity (BCVA) of 5 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent, 20/800) and 70 or fewer ETDRS letters read (Snellen equivalent, 20/40) in the study eye. METHODS: Patients were randomized 3:2 to suprachoroidally injected CLS-TA or sham treatment, with administrations at day 0 and week 12. MAIN OUTCOME MEASURES: The primary end point was improvement from baseline of 15 or more ETDRS letters in BCVA at week 24. The secondary end point was reduction from baseline in central subfield thickness (CST) at week 24. RESULTS: In the CLS-TA arm, 47% of patients gained 15 or more ETDRS letters in BCVA versus 16% in the control arm (P < 0.001), meeting the primary end point. Mean reductions in CST from baseline were 153 μm versus 18 μm (P < 0.001). No serious adverse events (AEs) related to treatment were reported. Corticosteroid-associated AEs of elevated intraocular pressure occurred in 11.5% and 15.6% of the CLS-TA and control groups, respectively. Cataract AE rates were comparable (7.3% and 6.3%, respectively). CONCLUSIONS: Patients in the CLS-TA study arm experienced clinically significant improvement in vision relative to the sham procedure, demonstrating the efficacy of suprachoroidal injection of CLS-TA for the treatment of ME in a vision-threatening disorder.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Yeh S, Khurana RN, Shah M, et al. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. Ophthalmology. 2020. PMID: 32173113. doi:10.1016/j.ophtha.2020.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。